Published Online: October 26, 2015. doi:10.1001/jama.2015.13802.
Study concept and design: Ambrose, Conway, Borek, Hyland, Villanti.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ambrose.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Day, Rostron.
Administrative, technical or material support: Ambrose, Borek, Villanti.
Study supervision: Conway, Borek, Hyland.
Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.
Funding/Support: Funded by the National Institute on Drug Abuse (NIDA), National Institutes of Health, and the US Food and Drug Administration (FDA), Department of Health and Human Services, under contract HHSN271201100027C.
Role of the Funders/Sponsors: Staff from the NIDA and the FDA contributed to the design and conduct of the study; management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and the decision to submit the manuscript for publication. The NIDA and the FDA were not directly involved in the collection of study data.
Disclaimer: The views and opinions expressed in this article are those of the authors and do not necessarily represent the views, official policy, or position of the US Department of Health and Human Services or any of its affiliated institutions or agencies.
Additional Contributions: We thank David Maklan, PhD, and Charles Carusi, PhD, from Westat Inc for contributions to study design and supervision, as well as data acquisition. We also thank Kristie Taylor, PhD, from Westat Inc for contributions to the study design and analytic support. Drs Maklan, Carusi, and Taylor received compensation for their contributions to the PATH Study.